Article
Factors associated with decisions about clinical BRCA1/2 testing.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Nov 2000
Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B
Abstract excerpt
Testing for mutations in BRCA1 and BRCA2 can provide important information about breast and ovarian cancer risk to a small but identifiable subgroup of women. Women who test positive for a BRCA1/2 mutation can pursue more aggressive cancer surveillance and prevention regimens. Among families with known mutations, women who test negative may avoid unnecessary interventions. Currently, little is known about the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.